Plans to build upon the UK-based Streams app have been announced.

Response deepened even without maintenance therapy.

GEMINI 1 and 2 results suggest noninferiority.

MaxRP and MaxRT yield similar cancer-specific and overall mortality in Gleason score 9-10 disease.

Results corroborate clinical trials, with pemetrexed-bevacizumab offering best results.

Medicines and Healthcare Products Regulatory Agency (MHRA) issues statement following results from discontinued trial.

Phase 2 trial shows 46% reduction in risk for progression or death.

Experts say better coordination of care is needed to reduce avoidable medication-related harm.

Pooled data from 2 phase 3 studies.

Ad-hoc study of phase 3 clinical trial.

Study found treatment effective in both hypogonadal and eugonadal men.

Real-world population data show higher risk within 90 days of systemic therapy.

A quick guide to personalizing cholesterol treatment for your patient.

The finding adds to the growing evidence that exposure to soy formula in early life may have detrimental effects on the reproductive system.